Skip to main content

Table 2 Drug repositioning candidates for Alzheimer’s disease (AD). Drugs showing a negative correlation score less than or equal to −0.40 and affecting more than 50% of the dysregulated pathways in AD

From: PS4DR: a multimodal workflow for identification and prioritization of drugs based on pathway signatures

Drug

DrugBank ID

Correlation Score

Affected Pathways (%)

Sirolimus (Rapamycin)

DB00877

−0.69

66.67

Pevonedistat

DB11759

−0.66

60.61

Nilotinib

DB04868

−0.64

60.61

Terfenadine

DB00342

−0.57

57.58

Doxylamine Succinate

DB00366

−0.57

54.55

Halcinonide

DB06786

−0.57

51.52

Promazine Hydrochloride

DB00420

−0.53

66.67

Mosapride

DB11675

−0.45

60.61

Pimozide

DB01100

−0.45

57.58

Ritanserin

DB12693

−0.45

57.58

Betamethasone

DB00443

−0.44

66.67

Cinacalcet Hydrochloride

DB01012

−0.43

72.73

Methapyrilene Hydrochloride

DB04819

−0.43

72.73

Trametinib

DB08911

−0.40

60.61